LIfT BioSciences appoints Antonin (Tony) de Fougerolles as Chairman of its Board of Directors
July 01 2024 - 2:00AM
LIfT BioSciences appoints Antonin (Tony) de Fougerolles as Chairman
of its Board of Directors
LIfT BioSciences appoints Antonin (Tony)
de Fougerolles as Chairman of its Board of Directors
London, 1 July 2024– LIfT
BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech
company preparing to start clinical trials for its first-in-class
allogeneic innate cell therapy, today announces the appointment of
Antonin (Tony) de Fougerolles, PhD as Chairman of its Board.
Tony brings over 25 years of biotech R&D
experience in building out drug pipelines and bringing new-to-world
therapeutic modalities to patients. He has most recently served as
CEO of Evox Therapeutics and previously, served as CSO of Ablynx,
where he led the company’s non-clinical R&D operations and
played a key role in the approval of the first single domain
antibody drug, caplacizumab and in building out a portfolio of
immuno-oncology and immunology products. Prior to this, Tony held
several leadership positions, including founding CSO at Moderna
Therapeutics where he developed and invented much of the
foundational science behind their revolutionary mRNA platform, CSO
at Tolerx, Inc and VP of Research at Alnylam. He currently serves
on the boards of etherna and Chimeron Bio and is also an advisor to
MiNA Therapeutics. Tony holds a PhD in Immunology from Harvard
University and a BSc in Microbiology & Immunology from McGill
University.
Alex Blyth, Chief Executive Officer of
LIfT BioSciences commented: “On behalf of LIfT’s Board of
Directors, I am pleased to welcome Tony to the Company as Chairman.
Tony has extremely relevant experience, having played a key role in
successfully bringing three new drug modalities to the market,
extensive experience in immuno-oncology, and has helped build
several multi-billion-dollar companies from start-up
stage. This wealth of experience will prove invaluable to LIfT
as we prepare to move into clinical trials for our allogeneic
first-in-class neutrophil-based immuno-cell therapy and other
exciting pipeline developments.”
Antonin (Tony) De Fougerolles, Chairman
of the Board commented: “I’m delighted to join LIfT at
such a crucial stage in its journey. The team at LIfT have been
leading the field in characterising and developing an
immuno-oncology therapeutics platform around a newly described
subset of neutrophils called Immuno-Modulatory Alpha Neutrophils
(IMANs). These IMANs dramatically outperform traditional
neutrophils in their tumour killing abilities by rapidly
infiltrating tumours and recruiting additional immune cells. As an
immunologist, it is not a surprise that neutrophils like other
immune cell types are also comprised of subsets of cells with
different functions. I look forward to using my varied experience
to support Alex and the team to advance LIfT’s IMANs through the
clinic towards the market as a new transformational therapy for
solid tumours.”
About LIfT BioSciences
LIfT Biosciences is a biotech bringing to market
a first-in-class proprietary immuno-cell therapy that overcomes the
limitations of current therapies in solid tumours by destroying
tumours both directly and indirectly. LIfT’s Immunomodulatory Alpha
Neutrophils (IMANs) turn the tumour microenvironment against the
tumour as they recruit the rest of the immune system to destroy the
tumour to give a durable response and lasting immunity. The
breakthrough N-LIfT platform is produced from a patented process
using exceptional stem cells (iPSC or HSC), a proprietary
enhancement media and genetic engineering. IMANs are believed to
possess a critical immune component that many cancer patients lack
to get the necessary immune response to achieve remission.The
company is developing a portfolio of CAR IMAN cell therapies and
IMAN combination therapies across oncology and other complementary
therapy areas. See www.liftbiosciences.com.
Further information
|
|
|
Investors & Media: |
|
|
Alex BlythICR ConsiliumMary-Jane Elliott, Namrata Taak, Lindsey
Neville |
+44 (0)7718 759116 |
ablyth@LIfTBioSciences.comliftbiosciences@consilium-comms.com |